Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
EXPE comes into the week with a sharply higher short position, a stock up 5% on the week, and the November 4 earnings date now just three weeks out.
The most notable development since last week's note is a step-change in short interest. Shares short rose 29% over the week, from roughly 6 million to 7.7 million, lifting the position to 6.6% of free float. The jump happened in a single session: between October 7 and October 8, shares short climbed by nearly 1.8 million. That is a meaningful addition, not a drift. The short score confirmed the shift, jumping from 41.6 to 46.3 between October 5 and October 12, the sharpest five-day move in the recent history. Despite all this, the borrow market offers no friction to new shorts. Availability sits at 1,258%, meaning roughly twelve shares are available to borrow for every one already lent out. The cost to borrow is 0.52%, well inside the range it has held all year. Options positioning has eased slightly from its most defensive levels: the put/call ratio of 1.28 is fractionally below the 20-day average of 1.32 and a clear step back from the 52-week high of 1.39 hit in late September. Taken together, the lending market reflects a fresh bearish addition at low cost, with options hedgers marginally less anxious than they were a fortnight ago.
The Street tells a mixed story. Bulls point to a business with $119.6bn in gross bookings, mid-20% adjusted EBITDA margins, and B2B volume growing above 20% for four consecutive quarters. The EV/EBITDA multiple of 7.8x and a trailing PE near 11.5x give the bull case a valuation cushion. Against that, the bear camp notes that management guided Q3 bookings growth of only 5% to 7%, a sharp deceleration from the 12% posted in the prior quarter. Vrbo and Hotels.com have yet to show consistent room-night recovery, and roughly two-thirds of revenue is tied to US consumers. The most recent analyst move was Wells Fargo cutting its price target from $307 to $275 on October 7. That move, flagged in last week's note, remains the clearest signal of Street caution. Most other analysts who moved targets did so after the August earnings print, lifting targets into the $320 to $430 range. The consensus mean of $336 sits roughly 23% above the current price of $273, but the gap between the Wells Fargo target of $275 and the Evercore ISI target of $430 reflects a genuinely divided view.
Institutional ownership is broadly passive, with BlackRock and Vanguard entities accounting for the largest declared positions. Two Vanguard vehicles filed fresh Schedule 13G disclosures in April, and The Vanguard Group's earlier 13G/A showed its consolidated stake falling from 12.85% to zero as it reorganised into separate entities. There is no 13D activist on the register. Insider activity was light and skewed toward sales. The chief legal officer and chief accounting officer sold a combined roughly $1.9m in shares in late August at prices around $323 to $335, well above the current level. These were discretionary sales, not 10b5-1 plan trades, though both were small relative to total holdings and carry significance scores of only 3 out of 10.
The last two earnings prints saw EXPE fall on the day in each case, by 2.8% and 1.8% respectively, before recovering over five days. The pattern suggests the market tends to sell the event first. Closest peer BKNG is essentially flat on the week while ABNB added 3.2%, meaning EXPE's 5% week was not simply a sector tide. Wikipedia page views carry a z-score of 1.16 against EXPE's own 90-day history, suggesting retail attention is somewhat elevated, though the alt data carries no measured leading indicator for revenue at this stage.
With the Q3 print on November 4, the next three weeks will test whether the short rebuild at 6.6% of float was early positioning ahead of a bookings deceleration or an overreaction to a single week's data move.
See the live data behind this article on ORTEX.
Open EXPE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.